Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey (NCT06680206), a registered phase not stated study. The primary outcome is Number of Participants According to Migraine Medication Type (Prescription Drug or Over the Counter [OTC]).

2. Clinical Question

The study’s broad aim is to compare patient-reported outcomes between rimegepant and triptan users with migraine in the United States. The survey source is the cross-sectional 2023 National Health and Wellness Survey, which included N=75,007 respondents. The study analysis is restricted to respondents meeting its migraine and medication-use criteria; the registry describes an enrollment of 1395 for this study. These figures refer to different record descriptions and should not be treated as interchangeable group counts.

The primary outcome is a medication-use classification, not a direct measure of symptom improvement, satisfaction, or disability. The additional outcomes make the planned comparison more relevant to participants’ reported experience and healthcare use, but their comparative estimates are not reported in the registry record. The record describes inverse probability of treatment weighting to adjust for differences between medication-user groups. Because treatment is not assigned randomly, any comparison remains observational and may be affected by measured or unmeasured differences between the groups.

3. Trial Design

This is a completed, cross-sectional observational study using data from the 2023 US National Health and Wellness Survey. The registry lists the study start as 2024-10-10 and primary completion as 2024-11-20. Although the analysis uses survey data collected for 2023, the registry describes the study’s own dates separately. It does not describe this as a prospective treatment trial.

The survey uses self-reported information from respondents recruited through an existing general-purpose web-based consumer panel. Recruitment routes include opt-in emails, co-registration with panel partners, e-newsletter campaigns, banner placements, and affiliate networks. Respondents agree to be panel members, register using a unique email address, and complete a demographic profile. These details describe the survey’s recruitment context; they do not establish that its respondents represent every person with migraine in the United States.

The analysis focuses on survey respondents who report physician-diagnosed migraine and acute use of rimegepant or triptans. The registry lists the study enrollment as 1395. The specific group sizes and participant flow are not reported in the registry record. It also cautions that the primary outcome’s IPTW-adjusted analysis population is a pseudo-set, so its participant counts differ from counts in participant flow and baseline information.

Rimegepant and triptans are compared as existing medication-use groups. Allocation is not stated as randomized, and the registry explicitly characterizes the comparison as not randomized. Inverse probability of treatment weighting (IPTW) is described as the approach for adjusting for covariate differences before outcomes are compared. The covariates, weight construction, diagnostics, and any additional adjustment procedures are not reported in the registry record.

The registry lists 53 outcome measures and 114 analyses. It describes outcomes spanning medication type, treatment satisfaction, healthcare resource utilization, quality of life, work productivity loss, and migraine-specific disability. The posted record does not give comparative estimates for these outcomes, so the study’s completion status does not by itself establish what the analyses found.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants According to Migraine Medication Type (Prescription Drug or Over the Counter [OTC]), measured over At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study..

The primary outcome is the number of participants classified by migraine medication type: prescription drug only, over-the-counter medication only, or both. It is assessed at the time of the survey during a one-year data-identification period in 2023; the record says available retrospective data were evaluated over approximately 1.41 months of the observational study. The registry describes analysis with IPTW to adjust for confounding by covariates.

A medication-use classification can describe how respondents’ reported migraine medication falls into these categories in the analysis population. It is not, by itself, a measure of treatment effectiveness, symptom severity, satisfaction, safety, or change over time. The outcome may provide context for medication use, while the other planned outcomes address patient experience and resource use more directly.

The registry states that the IPTW-adjusted population is a pseudo-set and that its participant counts differ from those in participant flow and baseline information. This matters because weighting can change the contribution of individuals to an analysis; a weighted analysis population should not be read as a simple count of unique observed participants. The category-specific counts and estimates are not reported in the registry record. Thus, the endpoint’s definition is available, but its observed distribution and the comparative results cannot be interpreted from this record alone.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does IPTW do?

Inverse probability of treatment weighting is a statistical approach used in observational comparisons to reduce measured differences between groups. In general, a model estimates how likely each person is to receive the treatment they actually received, based on recorded characteristics. People are then weighted according to those estimated probabilities. The intention is to create a weighted population in which the measured characteristics are more balanced across treatment groups than they were in the original data.

In this study, the registry says IPTW was used to adjust for covariates when comparing rimegepant and triptan users. It does not report which covariates were included, how treatment probabilities were modeled, whether weights were stabilized or trimmed, or whether balance was assessed. Without those details and diagnostics, the adequacy of the adjustment cannot be evaluated from the registry record.

Weighting does not make an observational comparison equivalent to random assignment. Its ability to reduce confounding depends on having relevant confounders measured and modeled appropriately. General statistical interpretation also depends on having enough overlap between groups in their treatment probabilities; where comparable people are uncommon, weights can become influential and estimates less stable. The record does not report overlap or weight diagnostics.

What does a weighted count represent?

The primary outcome classifies participants by reported migraine medication type: prescription drug only, over-the-counter medication only, or both. The registry states that the analysis population is adjusted with IPTW and is a pseudo-set, with participant numbers different from those in the participant flow and baseline sections. In general, weighted estimates represent a reweighted analysis population, not a straightforward tally of unique people. The actual category counts and weighted values are not reported in the registry record.

That distinction is important when reading any reported count or estimate. A weighted analysis can give different influence to different observations, so the number attached to the analysis should not automatically be interpreted as the number of respondents recruited or observed. The registry does not give enough detail to reconstruct how the weights relate to the reported outcome values.

How should uncertainty be read?

In general, a confidence interval describes a range of values compatible with the observed data and the assumptions of the statistical model. A narrower interval indicates greater precision under those assumptions; a wider interval indicates more uncertainty. A p-value, when reported, describes how unusual data at least as inconsistent with a specified null hypothesis would be under that hypothesis and model. Neither measure establishes that an observed association is causal.

Comparative estimates, confidence intervals, and p-values are not reported in the registry record. The direction, magnitude, and precision of the study’s findings therefore cannot be assessed from the record. A statistically significant result, if one were reported, would still need to be interpreted in light of confounding, outcome measurement, and the number of analyses.

Why can over-dispersion matter?

In general, count outcomes can vary more widely than a simple statistical model assumes. This is called over-dispersion. If present and not appropriately handled, it can make standard errors too small and confidence intervals too narrow, leading to overly confident inference. The registry describes the primary outcome as a count of participants by medication category, but does not report an over-dispersion assessment or a model for count data. Because the outcome is also a weighted categorical classification, the precise estimation approach would be needed to judge how uncertainty was handled.

What do planning illustrations mean?

Sample-size calculations are planning tools, not observed results. The registry’s described sample-size assumptions characterize an illustration based on an observed effect, using a two-sided significance level of 0.05, equal allocation, and a normal approximation; the target effect is expressed as a fraction of the observed effect. For time-to-event calculations, the stated quantity is a total number of events; other calculations refer to participants per arm. These assumptions do not establish that the observational study was designed or powered using that calculation. They are not observed power, and the registry does not report the study’s own sample-size justification.

The registry does not describe a detailed statistical analysis plan, including model specifications, handling of missingness, subgroup methods, or sensitivity analyses for the primary comparison. Some secondary outcomes are explicitly labeled sensitivity analyses, but their results and analytic details are not reported. Consequently, the methods that can be discussed are limited to the stated observational comparison and use of IPTW; further statistical choices are not reported in the registry record.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists 53 outcome measures and 114 analyses. When many outcomes or analyses are considered, the chance of observing at least one apparently unusual result can increase, even if no true association exists. General approaches to this issue include prespecifying a primary analysis, adjusting inference across selected comparisons, or clearly treating secondary findings as exploratory. The registry record does not report whether a multiplicity adjustment or other strategy was used. The primary outcome is identified, but detailed hypotheses and a prespecified hierarchy of analyses are not reported.

Missing-data handling is also not reported in the registry record. The survey is self-reported, but the record does not state how incomplete responses, missing covariates, or missing outcome values were treated. It does not say whether any imputation, complete-case analysis, or missingness sensitivity analysis was performed. These choices matter because the analyzed respondents may differ from those with missing information, and weighting itself requires usable covariate data or a specified method for handling their absence.

The record describes an eligible analysis population adjusted with IPTW and calls it a pseudo-set. It warns that the resulting participant numbers differ from those in participant flow and baseline information. The exact population definitions, group-specific counts, exclusions, and relationship between the unweighted survey respondents and weighted analyses are not reported in the registry record. That limits assessment of who contributed to each outcome and whether the analysis populations were consistent across the 114 analyses.

These reporting gaps do not show that multiplicity or missingness was mishandled. They mean that readers cannot evaluate the relevant procedures from the registry record. Comparative estimates and uncertainty measures are also not reported, so the implications of these issues for particular findings cannot be assessed.

11. What the Result Does, and Does Not, Mean

The registry record describes a completed observational comparison of self-reported outcomes among rimegepant and triptan users with physician-diagnosed migraine. It identifies a survey source, an eligibility focus, a primary medication-use classification, and IPTW as an adjustment method. The record does not report comparative outcome estimates, so no conclusion about the direction or magnitude of differences can be drawn from it.

The study’s question is relevant to patient-reported experience: it includes treatment satisfaction, healthcare resource utilization, quality of life, work productivity loss, and migraine-specific disability. Yet these are planned outcome domains, not findings in the registry record. The primary endpoint, a classification of medication use as prescription only, over-the-counter only, or both, does not by itself answer whether outcomes differed between medication groups.

Even if comparative estimates were available, an adjusted observational association would not, on its own, establish that medication use caused an outcome. IPTW can address measured covariate differences under its assumptions, but cannot guarantee balance on unmeasured factors or resolve limitations in self-reported measurement. The cross-sectional survey context also differs from a randomized trial that assigns treatment and prospectively follows participants.

The record’s completion status indicates that the study is marked completed, not that its results are conclusive or that all relevant analyses have been reported. The registry lists zero entries in its adverse-event fields for serious events, other events, and deaths in each medication group. Those registry entries should not be interpreted as evidence that no harms occurred: the record does not report how adverse events were collected or provide a safety analysis for this study.

Accordingly, the most defensible reading is descriptive: the study was designed to compare patient-reported outcomes using survey data and an IPTW approach, but the registry record does not report the comparative results needed to characterize those outcomes. It cannot establish superiority, equivalence, or absence of harm.

12. Why This Trial Matters Statistically

This study illustrates a common challenge in clinical and health-services research: comparing people who already use different treatments when treatment assignment was not randomized. Such analyses can address questions about patient-reported experience in real-world settings, but observed group differences may reflect both treatment and underlying differences between users.

IPTW makes the adjustment strategy explicit and gives readers a useful starting point for evaluating the intended design. The method also highlights why reporting matters. The covariates included, quality of balance after weighting, distribution of weights, and size of the effective analysis population all help determine whether an adjusted comparison is credible. These details are not reported in the registry record.

The study also draws attention to outcome definition. A primary count of medication-use categories is distinct from the patient-centered outcomes that motivate the broader comparison, such as quality of life, treatment satisfaction, and work impairment. Keeping the endpoint’s meaning separate from the study’s overall question prevents a medication classification from being mistaken for a measure of clinical benefit.

Finally, the registry lists many outcome measures and analyses. That breadth can be useful for describing multiple aspects of patient experience, but it increases the importance of prespecification, transparent multiplicity handling, and complete reporting. In this record, the design and analysis intention are described more fully than the actual results. The case therefore shows why a completed registry entry is not a substitute for outcome estimates, uncertainty intervals, and adequate documentation of analytic choices.

13. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation for interpretation is that comparative outcome values are not reported in the registry record. Without estimates and measures of uncertainty, neither the size nor precision of any difference between rimegepant and triptan users can be evaluated.

The study uses self-reported survey information from a web-based consumer panel. Migraine diagnosis, medication use, and patient-reported outcomes may be affected by recall or reporting differences. The registry describes multiple panel recruitment routes, but does not report response rates or information sufficient to assess selection into the survey and the eligible analysis group. The survey’s N=75,007 describes the source survey, not the analytic comparison; the study enrollment is listed as 1395.

The cross-sectional design limits assessment of timing between medication use and outcomes. The record gives a survey-time assessment and a retrospective evaluation timeframe, but does not report detailed exposure or outcome timing. It is therefore not possible to establish from this record whether medication use preceded the reported outcome.

IPTW can reduce confounding only to the extent that relevant covariates are measured and appropriately modeled. Covariate definitions, model details, balance results, weight diagnostics, and sensitivity analyses are not reported in the registry record. The record also does not report missing-data methods or a multiplicity strategy despite listing 53 outcomes and 114 analyses.

Finally, the registry’s adverse-event entries are all zero, but it does not describe event ascertainment or present a dedicated safety analysis. Those entries cannot establish that no adverse events occurred. Together, these limitations mean the record supports a description of the study’s design and intended methods, but not a detailed appraisal of its results.

14. Related Tutorials

15. Related Statistical Calculators

16. Sources

• ClinicalTrials.gov: Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey — NCT06680206.
• Registry record last updated 2026-01-22; status last verified 2026-01.
• Results first posted 2026-01-22.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

17. Record Summary

The registry lists NCT06680206 as a completed, cross-sectional study titled “Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey.” The sponsor is Pfizer. The listed study start is 2024-10-10, and primary completion is 2024-11-20. Enrollment is 1395.

The analysis uses the 2023 US National Health and Wellness Survey and focuses on respondents who self-report physician-diagnosed migraine and acute use of rimegepant or triptans. The primary outcome classifies participants by prescription-only, over-the-counter-only, or combined medication use. The registry describes IPTW for adjustment and lists patient-reported outcome domains including satisfaction, healthcare resource utilization, quality of life, work productivity loss, and migraine-specific disability.

The record lists 53 outcome measures and 114 analyses, but comparative outcome estimates and details of the statistical analysis plan are not reported in the registry record. The completed status therefore indicates study status, not the direction, size, or precision of findings.